Rx Product News (August 2017)

: Bristol-Myers Squibb

INDICATION: The FDA has approved Orencia (abatacept) to treat adults with active psoriatic arthritis in both intravenous and subcutaneous injection formulations.

DOSAGE FORM: IV: 250 mg; injection: 50 mg/ 0.4 mL, 87.5 mg/0.7 mL, 125 mg/mL in single-dose prefilled syringes, or 125 mg/mL in a single-dose prefilled ClickJect autoinjector.

FOR MORE INFORMATION: bms.com

COTEMPLA XR-ODTMARKETED BY: Neos Therapeutics

INDICATION: The FDA has approved Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets to treat attention-deficit/hyperactivity disorder in patients aged 6 to 7 years.

DOSAGE FORM: Extended-release orally disintegrating tablets: 8.6 mg, 17.3 mg, and 25.9 mg

FOR MORE INFORMATION: neostx.com

RITUXAN HYCELAMARKETED BY: Genentech

INDICATION: The FDA approved Genentech’s rituximab/hyaluronidase (Rituxan Hycela) combination treatment for adult patients with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia. DOSAGE FORM: Injection

FOR MORE INFORMATION: gene.com

: Emmaus Medical, Inc.

INDICATION: The FDA has approved Endari (L-glutamine oral powder) to reduce the severe complications of sickle cell disease in adult and pediatric patients 5 years and older. DOSAGE FORM: Oral powder

FOR MORE INFORMATION: emmausmedical.com